



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/68, G01N 33/574</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/60162</b> (43) International Publication Date: 25 November 1999 (25.11.99)
<p>(21) International Application Number: <b>PCT/US99/10548</b></p> <p>(22) International Filing Date: 12 May 1999 (12.05.99)</p> <p>(30) Priority Data: 60/086,265 21 May 1998 (21.05.98) US</p> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/086,265 (CIP) Filed on 21 May 1998 (21.05.98)</p> <p>(71) Applicant (for all designated States except US): <b>DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US).</b></p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): <b>ALI, Shujath [IN/US]; Apartment 357, 3475 Granada Avenue, Santa Clara, CA 95051 (US). SALCEDA, Susana [AR/US]; 4118 Cresendo Avenue, San Jose, CA 95136 (US). SUN, Yongming [CN/US]; Apartment 260, 869 S. Winchester Boulevard, San Jose, CA 95128 (US). CAFFERKEY, Robert [IE/US]; Apartment 4305, 651 Franklin Street, Mountain View, CA 94041 (US).</b></p>		<p>(74) Agents: <b>LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).</b></p> <p>(81) Designated States: <b>CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b></p> <p><b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: <b>A NOVEL METHOD OF DIAGNOSING, MONITORING, AND STAGING PROSTATE CANCER</b></p> <p>(57) Abstract</p> <p>The present invention provides a new method for detecting, diagnosing, monitoring, staging and prognosticating prostate cancer.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LJ	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

- 1 -

**A NOVEL METHOD OF DIAGNOSING,  
MONITORING, AND STAGING PROSTATE CANCER**

**FIELD OF THE INVENTION**

This invention relates, in part, to newly developed  
5 assays for detecting, diagnosing, monitoring, staging, and  
prognosticating cancers, particularly prostate cancer.

**BACKGROUND OF THE INVENTION**

Cancer of the prostate is the most prevalent  
malignancy in adult males, excluding skin cancer, and is an  
10 increasingly prevalent health problem in the United States.  
In 1996, it was estimated that in the United States, 41,400  
deaths would result from this disease, indicating that  
prostate cancer is second only to lung cancer as the most  
common cause of death in the same population. If diagnosed  
15 and treated early, when the cancer is still confined to the  
prostate, the chance of cure is significantly higher.

Treatment decisions for an individual are linked to  
the stage of prostate cancer present in that individual. A  
common classification of the spread of prostate cancer was  
20 developed by the American Urological Association (AUA). The  
AUA classification divides prostate tumors into four stages,  
A to D. Stage A, microscopic cancer within prostate, is  
further subdivided into stages A1 and A2. Sub-stage A1 is a  
well-differentiated cancer confined to one site within the  
25 prostate. Treatment is generally observation, radical  
prostatectomy, or radiation. Sub-stage A2 is a moderately to  
poorly differentiated cancer at multiple sites within the  
prostate. Treatment is radical prostatectomy or radiation.  
Stage B, palpable lump within the prostate, is further  
30 subdivided into stages B1 and B2. In sub-stage B1, the cancer  
forms a small nodule in one lobe of the prostate. In sub-  
stage B2, the cancer forms large or multiple nodules, or  
occurs in both lobes of the prostate. Treatment for both sub-  
stages B1 and B2 is either radical prostatectomy or radiation.

- 2 -

Stage C is a large cancer mass involving most or all of the prostate and is further subdivided into two stages. In sub-stage C1, the cancer forms a continuous mass that may have extended beyond the prostate. In sub-stage C2, the cancer  
5 forms a continuous mass that invades the surrounding tissue. Treatment for both these sub-stages is radiation with or without drugs. The fourth stage is metastatic cancer and is also subdivided into two stages. In sub-stage D1, the cancer appears in the lymph nodes of the pelvis. In sub-stage D2,  
10 the cancer involves tissues beyond lymph nodes. Treatment for both these sub-stages is systemic drugs to address the cancer as well as pain.

However, current prostate cancer staging methods are limited. As many as 50% of prostate cancers initially staged  
15 as A2, B, or C are actually stage D, metastatic. Discovery of metastasis is significant because patients with metastatic cancers have a poorer prognosis and require significantly different therapy than those with localized cancers. The five year survival rates for patients with localized and metastatic  
20 prostate cancers are 93% and 29%, respectively.

Accordingly, there is a great need for increasingly sensitive methods for the staging of a cancer in a human to determine whether or not such cancer has metastasized and for monitoring the progress of a cancer in a human.

25 In the present invention, methods are provided for detecting, diagnosing, monitoring, staging and prognosticating cancers, particularly prostate cancer via seven (7) Prostate Specific Genes (PSG). The seven PSGs refer, among other things, to native proteins expressed by the genes comprising  
30 the polynucleotide sequences of any of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7. In the alternative, what is meant by the seven PSGs as used herein, means the native mRNAs encoded by the genes comprising any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 or levels of the genes comprising

- 3 -

any of the polynucleotide sequences of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill  
5 in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the  
10 disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### **SUMMARY OF THE INVENTION**

Toward these ends, and others, it is an object of the  
15 present invention to provide a method for diagnosing the presence of prostate cancer in a patient which comprises measuring levels of PSG in a sample of cells, tissue or bodily fluid from the patient and comparing the measured levels of PSG with levels of PSG in preferably the same cells, tissue,  
20 or bodily fluid type of a control, wherein an increase in the measured PSG levels in the patient versus levels of PSG in the control is associated with prostate cancer.

Another object of the present invention is to provide a method of diagnosing metastatic prostate cancer in  
25 a patient which comprises measuring PSG levels in a sample of cells, tissue, or bodily fluid from the patient and comparing the measured PSG levels with levels of PSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured PSG levels in the patient versus  
30 levels of PSG in the control is associated with a cancer which has metastasized.

Another object of the present invention is to provide a method of staging prostate cancer in a patient which comprises identifying a patient having prostate cancer,

- 4 -

measuring levels of PSG in a sample of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured PSG levels with levels of PSG in preferably the same cells, tissue or bodily fluid type of a control. An increase  
5 in measured PSG levels in the patient versus PSG levels in the control can be associated with a cancer which is progressing while a decrease or equivalent level of PSG measured in the patient versus the control can be associated with a cancer which is regressing or in remission.

10 Another object of the present invention is to provide a method of monitoring prostate cancer in a patient for the onset of metastasis. The method comprises identifying a patient having prostate cancer that is not known to have metastasized, periodically measuring levels of PSG in a sample  
15 of cells, tissues, or bodily fluid obtained from the patient, and comparing the measured PSG levels with levels of PSG in preferably the same cells, tissue, or bodily fluid type of a control, wherein an increase in measured PSG levels versus control PSG levels is associated with a cancer which has  
20 metastasized.

Yet another object of the present invention is to provide a method of monitoring the change in stage of prostate cancer in a patient which comprises identifying a patient having prostate cancer, periodically measuring levels of PSG  
25 in a sample of cells, tissue, or bodily fluid obtained from the patient, and comparing the measured PSG levels with levels of PSG in preferably the same cells, tissues, or bodily fluid type of a control wherein an increase in measured PSG levels versus the control PSG levels is associated with a cancer  
30 which is progressing and a decrease in the measured PSG levels versus the control PSG levels is associated with a cancer which is regressing or in remission.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill  
35 in the art from the following description. It should be

- 5 -

understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging, and prognosticating cancers by comparing levels of PSG measured in a patient with levels of PSG in a control. What is meant by "levels of PSG" as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7. In the alternative, what is meant by "levels of PSG" as used herein, is levels of the native mRNA encoded by the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7 or levels of the gene comprising any of the polynucleotide sequence of SEQ ID NO: 1, 2, 3, 4, 5, 6 or 7. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, and includes determination of both normal and abnormal levels of PSGs. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing overexpression of PSG protein compared to control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers, including prostate cancer. Any of the seven PSGs may be measured alone in the methods of the invention, all together or in various combinations of the seven PSGs.

By "control" it is meant a human patient without cancer and/or non cancerous samples from the patient, also referred to herein as a normal human control; in the methods for diagnosing or monitoring for metastasis, control may also

- 6 -

include samples from a human patient that is determined by reliable methods to have prostate cancer which has not metastasized.

All the methods of the present invention may optionally include measuring the levels of other cancer markers as well as PSG. Other cancer markers, in addition to PSG, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. For example, simultaneous testing for increases in PSA as well as increases in PSG are also within the scope of the present invention and believed to provide a higher level of assurance that such cancer being tested is metastatic or the onset of metastasis has occurred.

#### ***Diagnostic Assays***

The present invention provides methods for diagnosing the presence of prostate cancer by analyzing for changes in levels of PSG in cells, tissues or bodily fluids compared with levels of PSG in cells, tissues or bodily fluids of preferably the same type from a normal human control, wherein an increase in levels of PSG in the patient versus the normal human control is associated with the presence of prostate cancer. Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the patient being tested has cancer is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as PSG, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal human control.

The present invention also provides a method of diagnosing metastatic prostate cancer in a patient having prostate cancer which has not yet metastasized for the onset of metastasis. In the method of the present invention, a human cancer patient suspected of having prostate cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a



- 7 -

variety of means known to those of skill in the art. For example, in the case of prostate cancer, patients are typically diagnosed with prostate cancer following traditional detection methods.

5 In the present invention, determining the presence of PSG in cells, tissues, or bodily fluid, is particularly useful for discriminating between prostate cancer which has not metastasized and prostate cancer which has metastasized.

Existing techniques have difficulty discriminating  
10 between prostate cancer which has metastasized and prostate cancer which has not metastasized and proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker levels measured in such cells, tissue, or bodily fluid are PSGs, and  
15 are compared with levels of PSG in preferably the same cells, tissue, or bodily fluid type of a normal human control. That is, if the cancer marker being observed is just PSG in serum, this level is preferably compared with the level of PSG in serum of a normal human patient. An increase in the PSG in  
20 the patient versus the normal human control is associated with prostate cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored  
25 has metastasized is one in which cells, tissues, or bodily fluid levels of the cancer marker, such as PSG, are at least two times higher, and most preferable are at least five times higher, than in preferably the same cells, tissues, or bodily fluid of a normal patient.

### 30 *Staging*

The invention also provides a method of staging prostate cancer in a human patient.

The method comprises identifying a human patient having such cancer and analyzing a sample of cells, tissues,  
35 or bodily fluid from such patient for PSG. Then, the method

- 8 -

compares PSG levels in such cells, tissues, or bodily fluid with levels of PSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in PSG levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of PSG is associated with a cancer which is regressing or in remission.

**Monitoring**

Further provided is a method of monitoring prostate cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for PSG; and comparing the PSG levels in such cells, tissue, or bodily fluid with levels of PSG in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in PSG levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Further provided by this invention is a method of monitoring the change in stage of prostate cancer in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissue, or bodily fluid from such patient for PSG; comparing the PSG levels in such cells, tissue, or bodily fluid with levels of PSG in preferably the same patient.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

**Assay Techniques**

Assay techniques that can be used to determine levels of gene expression, such as PSG of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays,

- 9 -

reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses and ELISA assays. Among these, ELISAs are frequently preferred to  
5 diagnose a gene's expressed protein in biological fluids. An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to PSG, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to  
10 PSG. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

To carry out the ELISA, antibody specific to PSG is  
15 incubated on a solid support, e.g., a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time PSG binds  
20 to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to PSG and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to PSG.  
25 Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish. Immobilized peroxidase, linked to PSG antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to  
30 the amount of PSG protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

A competition assay may be employed wherein antibodies specific to PSG attached to a solid support and  
35 labeled PSG and a sample derived from the host are passed over

- 10 -

the solid support and the amount of label detected attached to the solid support can be correlated to a quantity of PSG in the sample.

Nucleic acid methods may be used to detect PSG mRNA as a marker for prostate cancer. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e., gridding) can be used to both detect the expression of and quantitate the level of expression of that gene. In this approach, a cDNA encoding the PSG gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the PSG gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest.

Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of

- 11 -

gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and  
5 then using that material to generate a standard curve.

The above tests can be carried out on samples derived from a variety of patients' cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) such as from tissue biopsy and autopsy material. Bodily fluids useful in  
10 the present invention include blood, urine, saliva, or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum, or any derivative of blood.

#### **EXAMPLES**

15 The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or  
20 circumscribe the scope of the disclosed invention.

#### **EXAMPLE 1: PSGs**

Searches were carried out and PSGs identified using the following Search Tools as part of the LIFESEQ® database available from Incyte Pharmaceuticals, Palo Alto, CA:

25 1. Library Comparison (compares one library to one other library) allows the identification of clones expressed in tumor and absent or expressed at a lower level in normal tissue.

2. Subsetting is similar to library comparison but  
30 allows the identification of clones expressed in a pool of libraries and absent or expressed at a lower level in a second pool of libraries.

- 12 -

3. Transcript Imaging lists all of the clones in a single library or a pool of libraries based on abundance. Individual clones can then be examined using Electronic Northern

5 ESTs.

4. Protein Function: Incyte has identified subsets of ESTs with a potential protein function based on homologies to known proteins. Some examples in this database include Transcription Factors and Proteases. Some leads were

10 identified by searching in this database for clones whose component ESTs showed disease specificity.

Electronic subtractions, transcript imaging and protein function searches were used to identify clones, whose component ESTs were exclusively or more frequently found in

15 libraries from specific tumors. Individual candidate clones were examined in detail by checking where each EST originated.

Table 1:

20	SEQ ID	Clone ID #	Gene ID	
	NO:		#	
	1	1550426	244673	Protein Function (Transcription Factors)
	2	1255804	14878	Subsetting
	3	1808432	255819	Subsetting
	4	3930803	none	Subsetting
25	5	645804	235032	Subsetting
	6	1862352	221558	Subsetting
	7	1450626	236019	Subsetting

**EXAMPLE 2: Measurement of SEQ ID NO:1; Clone ID # 1550426; Gene ID #244673 (pro101)**

30 The example is carried out using standard techniques, which are well known and routine to those of skill in the art,

- 13 -

except where otherwise described in detail. Routine molecular biology techniques of the following example are carried out as described in standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

#### ***Relative Quantitation of Gene Expression***

Real-time quantitative PCR with fluorescent Taqman probes is a quantitative detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample are used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" is obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

To evaluate the tissue distribution, and the level of prol01 (SEQ ID NO:1) in normal and tumor tissue, total RNA was extracted from tumor and matched normal adjacent tissues and from unmatched tumor and normal tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction carried out using primers and Taqman probe specific to prol01 (SEQ ID NO:1). The results

- 14 -

were obtained using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of pro101 (SEQ ID NO:1) compared to the calibrator.

The absolute numbers are depicted in the following Table 2 as relative levels of expression in 12 normal tissues of pro101 (SEQ ID NO:1) compared to kidney (calibrator). These RNA samples were generated by pooling samples from a particular tissue from different individuals.

**Table 2: Relative levels of pro101 Expression in Pooled Samples**

Tissue	NORMAL
Brain	1.2
Heart	2
Kidney	1
Liver	7.2
Lung	48.2
Mammary	2.5
Prostate	1418.4
Spleen	1.6
Small	1.9
Testis	57.3
Thymus	1.3
Uterus	7.6

The relative levels of expression in Table 2 show that for the PSG pro101 (SEQ ID NO:1) mRNA expression is more than 20 fold higher in the pool of normal prostate compared with the other 11 normal tissue pools analyzed. These results demonstrate that mRNA expression of the PSG is highly specific for prostate.

The tissues shown in Table 2 correspond to pools of samples from different individuals. The tissues shown in the following Table 3 were obtained from individuals and are not pooled. Hence the values for mRNA expression levels shown in Table 2 cannot be directly compared to the values shown in Table 3.



- 15 -

The absolute numbers in Table 3 are relative levels of expression of pro101 (SEQ ID NO:1) compared to kidney (calibrator), in 60 pairs of matching samples. Each matching pair contains the cancer sample for a particular tissue and the normal adjacent sample for that same tissue from the same individual. The results from 3 unmatched ovary tumor, 3 unmatched normal ovary, 1 unmatched mammary tumor and 1 unmatched normal mammary gland are also shown.

**Table 3: Relative Levels of pro101 Expression in Individual Samples**

10

15

20

25

30

35

40

45

TISSUE	CANCER	MATCHING	UNMATCHED
Prostate 1	103.9	0	
Prostate 2	2219	84.2	
Prostate 3	5048.2	3623.6	
Prostate 4	11052.3	2029.4	
Prostate 5	229.1	41.1	
Prostate 6	57.9	25.3	
Prostate 7	58.5	57.069	
Prostate 8	1074.6	610.8	
Prostate 9	32.7	79.3	
Prostate 10	15.8	2.09	
Prostate 11	436.4	438	
Prostate 12	49.5	59.3	
Prostate 13	128	56	
Bladder 1	0	0	
Bladder 2	0	0	
Bladder 3	0.7	0	
Colon 1	0	0	
Colon 2	0	0	
Colon 3	0	0	
Colon 4	3.3	1.9	
Colon 5	0.1	0.8	
Colon 6	0	0	
Lung 1	0	0	
Lung 2	0.5	1.6	
Lung 3	1.4	2.1	
Lung 4	0	0	
Lung 5	0	0	
Kidney 1	0	0	
Kidney 2	0	0	
Kidney 3	0	0	
Kidney 4	0	0	
Liver 1	1.5	5.7	
Liver 2	26.9	7.9	
Liver 3	0	0	

- 16 -

	Pancreas 1	0.9	0.9	
	Pancreas 2	3	0	
	Pancreas 3	0	0	
	Pancreas 4	0	0	
5	Pancreas 5	0	0	
	Stomach 1	0	0	
	Stomach 2	0	0	
	Stomach 3	0	0	
	Stomach 4	0	0	
10	Stomach 5	0	0	
	Sm Int 1	0	0	
	Sm Int 2	0	0	
	Testis 1	0	0	
	Mammary 1	4	0	
15	Mammary 2	5.6	0	
	Mammary 3	0.5	0	
	Mammary 4	0.4	0	
	Mammary 5	0.5		
	Mammary 6			0
20	Endo 1	1.6	7.6	
	Endo 2	0	0	
	Endo 3	0	0	
	Endo 4	0.3	0.2	
	Endo 5	5.8	5	
25	Uterus 1	0	0	
	Uterus 2	0	0	
	Uterus 3	0	0	
	Uterus 4	2.2	2.6	
	Ovary 1	1.4		
30	Ovary 2			11.6
	Ovary 3	1.5		
	Ovary 4			22.9
	Ovary 5	0		
	Ovary 6			1.8

35 Among 128 samples in Table 3 representing 14 different tissues, the higher levels of expression are consistently in prostate tissues. These results confirm the tissue specificity results obtained with normal samples shown in Table 2. Table 2 and Table 3 represent a combined total of

40 140 samples in 18 human tissue types. Sixty-eight samples representing 13 different tissue types excluding prostate had no detected prol01 mRNA (Table 3). In 4 tissues (stomach small intestine kidney and testis) no prol01 (SEQ ID NO:1) mRNA was detected for any sample tested from individuals

45 (Table 3). Expression of this PSG was detected in testis in the pooled normal sample (Table 3). The median expression in

- 17 -

prostate cancer samples in Table 3 is 166.5 units. Excluding Ovary 4 (Normal), only 1 sample in Table 3, Liver 2 (Cancer), is greater than 10% of this value.

Comparisons of the level of mRNA expression in prostate tumor samples and the normal adjacent tissue from the same individuals are also shown in Table 3. The PSG pro101 (SEQ ID NO:1) is expressed at higher levels in 9 of 13 (69%) prostate cancer tissues (Prostate 1, 2, 3, 4, 5, 6, 8, 10 and 13) compared with the corresponding normal adjacent tissue. The level of expression of this PSG is lower in prostate tumor compared to normal adjacent tissue in two samples (Prostate 9 and 12). Equivalent levels of expression were detected in two matched samples (Prostate 7 and 11). Previous mRNA expression analysis for genes coding for the diagnostic markers PSA and PLA2 showed higher expression of the mRNA in 40% to 80% of the tumor samples compared to matching normal adjacent tissue. Higher expression in the tumor sample compared to the corresponding normal adjacent tissue is observed for Bladder 3, Colon 4, Liver 2, Pancreas 2, Endometrium 5 and. Mammary 1, 2 and 3. Higher expression in the normal adjacent samples is observed for Colon 5, Lung 2, Lung 3, Liver 1, Endometrium 1 and Uterus 4. However, the levels detected are in most cases comparable amongst the different tissues and low compared to levels found in most prostate tissues.

The high level of tissue specificity, plus the mRNA overexpression in 9 of 13 of the prostate tumor samples tested compared to the normal adjacent tissues are believed to make the PSG, pro101 (SEQ ID NO:1) a good diagnostic marker for detection of prostate cancer using mRNA.

- 18 -

**What is Claimed is:**

1. A method for diagnosing the presence of prostate cancer in a patient comprising:

(a) measuring levels of PSG in a sample of cells,  
5 tissue or bodily fluid obtained from the patient; and

(b) comparing the measured levels of PSG with levels of PSG in a sample of cells, tissue or bodily fluid obtained from a control, wherein an increase in measured levels of PSG in the patient versus the PSG levels in the control is  
10 associated with the presence of prostate cancer.

2. A method of diagnosing metastatic prostate cancer in a patient comprising:

(a) measuring levels of PSG in a sample of cells,  
15 tissue, or bodily fluid obtained from the patient; and

(b) comparing the measured levels of PSG with levels of PSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in measured PSG levels in the patient versus the PSG levels in the control is associated  
20 with a cancer which has metastasized.

3. A method of staging prostate cancer in a patient comprising:

(a) identifying a patient suffering from prostate cancer;

25 (b) measuring levels of PSG in a sample of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of PSG with levels of PSG in a sample of cells, tissue, or bodily fluid obtained from a control, wherein an increase in the measured levels of  
30 PSG versus the levels of PSG in the control is associated with a cancer which is progressing and a decrease in the measured levels of PSG versus the levels of PSG in the control is associated with a cancer which is regressing or in remission.

- 19 -

4. A method of monitoring prostate cancer in a patient for the onset of metastasis comprising:

(a) identifying a patient having prostate cancer that is not known to have metastasized;

5 (b) periodically measuring PSG levels in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the periodically measured levels of PSG with levels of PSG in cells, tissue, or bodily fluid obtained from a control, wherein an increase in any one of the  
10 periodically measured levels of PSG in the patient versus the levels of PSG in the control is associated with a cancer which has metastasized.

5. A method of monitoring changes in a stage of prostate cancer in a patient comprising:

15 (a) identifying a patient having prostate cancer;

(b) periodically measuring levels of PSG in samples of cells, tissue, or bodily fluid obtained from the patient; and

(c) comparing the measured levels of PSG with levels  
20 of PSG in a sample of the same cells, tissue, or bodily fluid of a control, wherein an increase in any one of the periodically measured levels of PSG versus levels of PSG in the control is associated with a cancer which is progressing in stage and a decrease in any one of the periodically  
25 measured levels of PSG versus the levels of PSG in the control is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the PSG comprises SEQ ID NO:1.

## SEQUENCE LISTING

<110> Ali, Shujath  
 Salceda, Susana  
 Sun, Yangming  
 Cafferkey, Robert

<120> A Novel Method of Diagnosing, Monitoring and Staging  
 Prostate Cancer

<130> DEX-0034

<140>

<141>

<150> 60/086,265

<151> 1998-05-21

<160> 7

<170> PatentIn Ver. 2.0

<210> 1

<211> 1936

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (1908)

<400> 1

```

aatggtatgc caacttaagt atttacaggg tggcccaaagt agaacaagat gcactcgctg 60
tgatttttaag acaagctgta taaacagaac tccactgcaa gagggngggc cgggccagga 120
gaatctccgc ttgttcaaga caggggccta aggagggtct ccacactgct gctaggggct 180
gttgcatTTTT tttattagta gaaagtggaa aggcctcttc tcaactTTTT tcccttgggc 240
tgagagaattt agaatcagaa gtttcctgga gttttcaggc tatcatatat actgtatcct 300
gaaaggcaac ataattcttc cttccctcct tttaaaattt tgtgttcctt tttgcagcaa 360
ttactcacta aagggttca ttttagtcca gatttttagt ctggctgcac ctaacttatg 420
cctcgcttat ttagcccgag atctggtctt tttntgtnt ttttttntt tccgtctccc 480
caaagcttta tctgtcttga ctttttaaaa aagtttgggg gcagattctg aattgggcta 540
aaagacatgc atttttaaaa ctaggcaact tcttatttct ttcctttaaa aatacatagc 600
attaaatccc aaatcctatt taaagacctg acagcttgag aaggtcacta ctgcatttat 660
aggaccttct ggtggttctg ctgttacgtt tgaagtctga caatecttga gaatctttgc 720
atgcagagga ggtaagaggt attggatttt cacagaggaa gaacacagcg cagaatgaag 780
ggccaggctt actgaggctg tccagtggag ggctcatggg tgggacatgg aaaagaaggc 840
agcctaggcc ctggggagcc cagtccactg agcaagcaag ggactgagtg agccttttgc 900
aggaaaaggc taagaaaaag gaaaaccatt ctaaaacaca acaagaaact gtccaaatgc 960

```

```

tttgggaact gtgtttattg cctataatgg gtccccaaaa tgggtaacct agacttcaga 1020
gagaatgagc agagagcaaa ggagaaatct ggctgtcctt ccattttcat tctgttatct 1080
caggtgagct ggtagagggg agacattaga aaaaaatgaa acaacaaaac aattactaat 1140
gaggtacgct gaggcctggg agtctcttga ctccactact taattccgtt tagtgagaaa 1200
cctttcaatt ttcttttatt agaagggccca gcttactgtt ggtggcaaaa ttgccaacat 1260
aagttaatag aaagttggcc aatttcaccc cattttctgt ggtttgggct ccacattgca 1320
atgttcaatg ccacgtgctg ctgacaccga ccggagtact agccagcaca aaaggcaggg 1380
tagcctgaat tgctttctgc tctttacatt tcttttaaaa taagcattta gtgctcagtc 1440
cctactgagt actctttctc tcccctcctc tgaatttaaa tctttcaact tgcaatttgc 1500
aaggattaca catttcactg tgatgtatat tgtgttgca ngaaaagaaa aaagtgtctt 1560
tgtttaaaat tacttgggtt gtgaatccat cttgcttttt cccatttggg actagtcatt 1620
aaccatctc tgaactggta gaaaaacatc tgaagagcta gtctatcagc atctgacagg 1680
tgaattggat ggttctcaga accatttcac ccagacagcc tgtttctatc ctgtttaata 1740
aattagtttg ggttctctac atgcataaca aacctgtct caatctgtca cataaaagtc 1800
tgtgacttga agtttagtca gcacccccac caaactttat ttttctatgt gttttttgca 1860
acatatgagt gttttgaaaa taaagtaccc atgtctttat taaaaaanaa aaaaaagggc 1920
ggccgccgac tagtga 1936

```

&lt;210&gt; 2

&lt;211&gt; 637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

```

gtaggggcag acttactgcc ttgaacgaaa gacgatggtc ctgctcagc ctactccaa 60
ttatgttcct ctaggtgggg caggtagggg gtccagcttc ctgcttgctg gtggttcagg 120
tcatgcgtcc agccttgtec cttctgacct gggccctacc cacggggaaa tgttccata 180
gcagaagaat cagccccaca gtgcaggggt gtgttagtgg ggaacgggct ctgggctcct 240
gtgggaacca gggacccctt atcttggtag cggtcattgg atgtatcccc agctcatgcc 300
tgtgtctgtc ttggcccggt tggtcaccct gtgttcatct ctctcccagc catggcctct 360
caaaactggg ttttcgtctc cctatgaggg ggtcctggta tgtacgcgtt cgggtggccc 420
gcggtgcatg tctcccggtg cagtgcagtc tgggggtccc tggggccctg ggcccctcgt 480
aggatagaca gagcctgtcc taaccttccg gaagtgcag ctggggaggc cccttgctg 540
ctgaccttct gtgctcagga cgactaatcg gccacatgac caccactctg tcccatggga 600
ttcctagaga agtctcacta agagcccagc aactca 637

```

&lt;210&gt; 3

&lt;211&gt; 2693

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (2266) .. (2512)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (586)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1480)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1532)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1562) .. (1566)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1569)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1571)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (1631)

&lt;400&gt; 3

```

gctcctacag ccgcatctgc gttaacatag catccctatg gccactgtct cccttgatcc 60
ccacagccat cctaggagaa aggcagaatg tcataatttg ctaaaaggga tgctgaggct 120
ctgggaggga aagggaacttg cctaaagccc cagggtgaag cagcatctct ggactcccag 180
tccagtgate ttgcccaata ctttgctgct tgcctataacc cctctaactt ggtcaacagc 240
acatcacagg gcaagcccaa tccctgcttc atttttatat atgggcgctg gtccacagcc 300
ccactctcca gccatttgga aacaaaaaca gatgctattg ttcttcctta gagaacgtgg 360
ccagtggaga cggcacactg gaaatcagag tgaatgttct tgaaagaggg tcacgggtca 420
acaaggccca gccaaaggat gcagtagaac cattttcctt agaaatcttt gggagtgaag 480
taggcttcag ccactaccca tccctgccct tgcggctacc actaccccat tagtttagac 540
agggctcgggc ggggaggggt gtggagaaga aatgagcttg cctgtngccc ccaggctccc 600
tctgtcctag ctcaggctctg ggtgccattc tttaactcgt tgtgctcgtc cacgcacaca 660
tcacacacct tgctggtcac acagtcacag actgcctct gctcctgtgg tccagtggcc 720
ggacaccccc tgggatggct caaaggagtc aggacttgga agtggggaca tcagggtagc 780
tgaaggaaat ccacacaccc agagcatctc ggagttcaga ctctcagacc tgaagtaggc 840
gcccccgga ctgggctagg agttggacgg aatggaggat ggaggacagc gagaagaaag 900
gaagagaaat gcaaagtgtg ggcagccgcc aagagtgaat atagaggga gtgtcatgca 960
agtgtcggac agaaggcggc aggtgggacg agccccacag cccctcctc aaaaacgacc 1020
acctccagga ctcagtgate cctggggggc aggtctctgcc agccctcggc cacacgtggc 1080
tccggcacc atgggtcccag tgccttgat ggagacggcc agttctggcg gccagatgtg 1140
gtgctctgga atccagtccc atttccttcc tggccacgcc tgttccagcg gcctctttgg 1200
ctgcattcag cccctactta cctggggacc ccggctgggg cacaagagca ccaggggggt 1260
agggcccaaa gggatcaggg gaagcctctg gcctggaggg tatggggcac gcttcccaa 1320

```



```

gggcggaaccc ggcaggagga agcccaggag ctgggtcctg ccgcccagga gctggggccct 1380
gccaccacagg ccgggctagg gacatggcag ggcctgggca tcctgacgct ggacttgggc 1440
gacctgggag gcacagggag gggagagatg ggcggcccn acccagcgca gtgccggcca 1500
caccccaagg cggttgccag agcttaaggc cnggccccag caggagaaca tcccagctcc 1560
annnnncnc nccgcagcca gtgctccttg tcaagctccc cccgtcactc cagggtggag 1620
ccaccccggt nagggggtgt gccacttgcc cccagggcac tcctctgggc atcccgggtg 1680
ggggattttg gggcgtggg gggcagtctc tggtagctgt gtgctcagg gatgctctgc 1740
acctgcaacc aggtgtcgtc cacgggcggg ggcaggggca tggtagacagt ggtcctgttg 1800
atgtcaccca tgatgctgag cgctccttc agcgcgtggg gcatgtgcag catctcgtcg 1860
tgctgctgtg cctgctctgc caactcctcc atcagtgtgt tctggttccc acatgagtac 1920
atattggcca gcggctccga gatgatgaac tccggggtct gagagtggg aaacagggaa 1980
gaaggttggg acctggtgcc tgtgccgcc tggctgcctt gctggggccct tctgggactg 2040
tgcgtggac ttggagcccc ttggagtatg gcttttcaca cgggcttcta taccgcttcg 2100
actggaagat ccacctcccc actgcctttt ctcactcaga tggggacacc gaggtccaga 2160
ggaaaagaca cctgtcaaat gtcacagatc tgggagggga cttaagacct atcatgccaa 2220
gaggacacct gtctactcag ttttttttg gtggggcggg gggcgnnnnn nnnnnnnnnn 2280
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2340
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2400
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 2460
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnggagttgg 2520
agttgatgcc tggatacagg agctctgtgg gtgggagtga gacaaaacac agggctcctga 2580
gctctgggga ccaagcaatg tcctctgggtg aaaaaaatcc tggacttgct ggcagaagat 2640
ttgcctctta cttgccatgt gctctgaata catttacctg ccctctggga aaa 2693

```

&lt;210&gt; 4

&lt;211&gt; 292

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (284)

&lt;400&gt; 4

```

aagaatatga gatttgctta gaaatgaagg actggaagga gccacagag ttatttttta 60
aactatccag taaggcttag agggtttcaa tcagaaatat gtgttagggg aaaaaatgca 120
ctttttctat attaaaaaat attattttct tcttttaaag gtaaagcatt cctattgtga 180
agaattgaga aaatacagaa aagtacaaag aaaaacatta cctacaactc caccatccgt 240
gattatcact gttcacattt gtggctcatt tttcagatg tctnttattt aa 292

```

&lt;210&gt; 5

&lt;211&gt; 2694

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (52)

<220>  
<221> unsure  
<222> (74)

<220>  
<221> unsure  
<222> (76)

<220>  
<221> unsure  
<222> (80)

<220>  
<221> unsure  
<222> (92)

<220>  
<221> unsure  
<222> (97)

<220>  
<221> unsure  
<222> (123)

<220>  
<221> unsure  
<222> (132)

<220>  
<221> unsure  
<222> (173)

<220>  
<221> unsure  
<222> (217)

<220>  
<221> unsure  
<222> (257)

<220>  
<221> unsure  
<222> (2539)

<400> 5  
tactatattg ctcagcattt ctaagtattc tctaagtgc ctttatttat gntttaaaat 60  
agctctctta ccnngntgcg ncgactagaa gancttgntt taggaaacaa tgaaatatat 120

```

aanttgccag antcaattgg agccctctta catctaaaag atctctgggt ggntggaaat 180
caactgtcag aattacctca ggaaatagga aatctgnaga acctgctgtg tttagatgtc 240
tctgaaaaca gggttgnaag acttcctgaa gaaatcagtg gcctgacttc attaacggat 300
ttagtcatatt cccagaactt attagaaacg attccggatg gcattggaaa actaaagaaa 360
ctgtcaatct tgaagggtgga tcagaataga ctcacacagt tgcctgaagc agttggggaa 420
tgtgaaaagtc tcaactgagtt agttcttaca gaaaatcagc tcctgaccct gcctaaaagc 480
attggaaaac taaagaagtt gagcaacttg aatgcagaca gaaataaatt agtgtcctta 540
ccaaaagaga tcggcgggtg ctgcagcctc actgtgttct gtgtacgtga caacagacta 600
actcggatac ctgcagaggt gtcacaggca acagaacttc atgtcctgga tgtggcaggg 660
aacaggttgc tgcactctacc tttatccctg actgccttga agttgaaggc tctgtggcta 720
tctgacaacc agtcccagcc cctgcttaca ttccagacag acacagacta caccacagga 780
gagaagattt taacctgtgt cttacttctt cagctgcctt ctgaacctac ttgtcaagag 840
aatctgcctc gctgtggtgc actggagaac ttggtaaatg atgtctctga tgaagcctgg 900
aacgagcgtg ctgtcaacag agtcagtgcg atccgatttg tggaggatga gaaagatgaa 960
gaagacaatg agacgagaac acttctaagg cgagccactc cacaccagg ggagttaaag 1020
cacatgaaaa agacagtgga gaatttacgg aatgacatga atgtgtctaa aggactggac 1080
tcaaacaaaa acgaggtcaa tcatgccatt gaccgagtga ccacttctgt gtagagtttc 1140
acctccaagt tttacctcct gtgtcttctt ctgctgtoga gacgttctctg tctgtctccc 1200
gggagcctca cgtgtctcct gtccctaacca gccccgcgc gccatcttcc cgtggagtgt 1260
ggggaagctg ctgtctccca ggaagtgcct tactcatccc gcaaccagtc agcgcaccag 1320
tggctctccg gtgtgatttt tttttttttt aatttcagtt gtttgaata agtagaatac 1380
actactgtaa acatacgacc tttgtttttg tcttatgttg gggtaaagga aagcaggaag 1440
gggaattttt atcctcctcc cttccgtaaa gtgctgggat attttgaatc cccaagttc 1500
ccttggacct actgatgaga gatagtttta tgtatgggga aaaatggata ctttttaaac 1560
cttttttggc agctcagatg gtgtaaattt taaaattttg tataggtatt tcataacaaa 1620
aatatgtatt tcttttttgt tattttatct tgaaaacggt acatatttta gtatttgtgc 1680
agaaaaacaa gtcctaaagt atttgttttt atttgtacca tccacttgtg cttactgta 1740
tcctgtgtca tgtccaatca gttgtaaaca atggcatctt tgaacagtgt gatgagaata 1800
ggaatgtggt gttttaaagc agtggtgcat tttaatcagt aatctacctg gtggatttgt 1860
ttttaaccaa aaagatgaat tatcaatgat ttgtaattat atcggttgat tttttttgaa 1920
aagatgaacc aaaggatttg actgctaata ttttattcct tacacttttt ttctgaataa 1980
gtctctcata atgagtgcag tgtcagactg tgcctactct gatggtatgt gccatttgta 2040
aaataaaata gagcagaaaa acacaaaaag agaactctgg ttcagacatt cagtgggcaa 2100
gtaaattatg gactgcaaaa taatgatttt tattcaagaa agctttaaaa gttttatatac 2160
cagatatata accacaataa agcaaaaataa cctactatca aaatagaaat gttgctatct 2220
ttataagtgc aatttaattt gtaaataagag tttgaatcaa agtatcacia aatactgctt 2280
caagatttaa ttttaaatct gctaatttaa gggatatttg gaaaagtttt ggtgtgtttc 2340
tgttgatttc ttttttgtat gctgtgataa aagagaaatg aaaagtcca gtcactgtgt 2400
gggtgtctagg aaaatcatat atattttttt ctccaagaaa taaattcatc ctggacattg 2460
gccatacagc tttttaaaat tattactttg tatgttcaag tgatagcagg tagccaaatt 2520
ctttgacagt gtgctctgnt ctgttaaata tctaaattac ccgtcagttg tgagtgcact 2580
cctgtgggac ttgcattcac atggggcaga gcccagaatt gcctttgact ctggctagta 2640
attttgggtt gtggctatct ggccaattgg actccttata aaccctctt caac 2694

```

&lt;210&gt; 6

&lt;211&gt; 1335

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (17)

&lt;400&gt; 6

```

tcatatagta ggaaganaag cacctagggtt tgaggccagg gctggctgct gtcagaacct 60
agggccctccc ctgccttgct ccacacctgg tcagggggaga gaggggagga aagccaaggg 120
aagggaacctt actgaaaaca aacaagctgg gagaagcagg aatctgctgct cgggttcgcg 180
agatgcagag gttgaggtgg ctgcgggact ggaagtcatt gggcagaggt ctcacagcag 240
ccaaggaacc tggggcccgct tcctccccc tccaggccat gaggattctg cagttaatcc 300
tgcttgctct ggcaacagggt cttgtagggg gagagaccag gatcatcaag gggttcgagt 360
gcaagcctca ctcccagccc tggcaggcag cctgttcga gaagacgcgg ctactctgtg 420
gggcgacgct catcgcccc agatgggctcc tgacagcagc ccaactgcctc aagccgtggc 480
cgctacatag ttacacctgg gcagcacaac ctccagaagg aggagggtg tgagcagacc 540
cggacagcca ctgagtcctt cccccacccc ggcttcaaca acagcctccc caacaaagac 600
caccgcaatg acatcatgct ggtgaagatg gcatcgccag tctccatcac ctgggctgtg 660
cgacccctca ccctctcctc acgctgtgtc actgctggca ccagctgcct catttcggc 720
tggggcagca cgtccagccc ccagttacgc ctgcctcaca ccttgcgatg cgccaacatc 780
accatcattg agcaccagaa gtgtgagaac gcctacccc gcaacatcac agacaccatg 840
gtgtgtgccg gcgtgcagga agggggcaag gactcctgcc agggtgactc cgggggccc 900
ctggtctgta accagtctct tcaaggcatt atctcctggg gccaggatcc gtgtgcgac 960
acccgaaagc ctggtgtcta cacgaaagtc tgcaaataatg tggactggat ccaggagacg 1020
atgaagaaca attagactgg acccaccac cacagcccat caccctccat ttccacttgg 1080
tgtttggttc ctgttcactc tgtaataaag aaaccctaag ccaagaccct ctacgaacat 1140
tctttgggccc tctgggacta caggagatgc tgtcacttaa taatcaacct ggggttcgaa 1200
atcagtgaga cctggattca aattctgcct tgaaatattg tgactctggg aatgacaaca 1260
cctggtttgt tctctgttgt atccccagcc ccaaagacag ctcttgccat atatcaagtt 1320
tcaataaata tttct                                     1335

```

&lt;210&gt; 7

&lt;211&gt; 1079

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (268)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (688)

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (700)

&lt;400&gt; 7

tttttgaaga	atgccctgca	aggcatcaac	tggaatgtgt	ttattaccaa	acaagacaga	60
agagaaccag	ggcctgactt	ggcagtggcc	ccaggctgca	tgggctcag	taggctcaga	120
ccggccccag	gagtgggaga	gcccagagaa	gagggaaaaa	gagtagtggc	caggaggggt	180
ctggctggga	catgccactc	tgggccatca	gcttctggat	ccactcaaag	tggtaggctga	240
tattggtgta	gacaccgggc	cgattggnc	gaccacagcc	cactccccag	ctcacgactc	300
caatctgata	ccacagtcca	ttcttgttac	aggccaaggg	tccacctgag	tcaccgaagc	360
aggcatectt	cccgccttgg	gcattgccag	cacaaacat	gtctccaaag	atgtccttgc	420
ggaaactgta	cttgaggaag	aggtggttgc	acatagagtt	gtttatgatg	gcgacctgaa	480
cttcctggag	gggtgtggga	gatggcagtg	cctcatcctc	tttgatgtac	ccccagccag	540
tcaccagca	gtctgtccgg	ttctcaaact	caaagtgtga	ggcctggaga	cagatgggct	600
ggatgtgttt	agtgtaggtg	acaggtgcag	acagcttcac	caaggcaatg	tcataggggtg	660
aattccccag	ttagcgaggg	ctcagatnga	tattcgatan	gaagtaacgg	gtgtagtagg	720
cctgcaggct	ccagaaggat	ggcatggaag	tcagctggcc	aaactggacc	atccaccgg	780
agggatcact	aaggtcacta	taggtttcaa	agcagtgcgc	cgccgtgagt	gcccagcgg	840
ggctgagcag	gtcactccg	catacgtggg	aatcccacag	gcgcaggctc	ccctgccacg	900
gccaacgccc	gagttcggcg	tcctctccac	ccacgatgcg	cgacgtgatg	acccgtcggc	960
cgcatggtcc	tgataagggc	gccgcctcct	gcgactccgg	cttcctgagt	ccagcccag	1020
ccagcagcag	cgccagcagc	agcgccccgc	gcgcgcccat	ggcctcctct	cccgcgggtg	1079

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/10548**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12Q 1/68; G01N 33/574

US CL : 435/6, 7.23

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 7.23

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG, APS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,506,106 A (CROCE et al.) 09 April 1996, col. 1, lines 50-65.	1-5
X	DEGUCHI, T. et al. Detection of Micrometastatic Prostate Cancer Cells in the Bone Marrow of Patients with Prostate Cancer. British Journal of Cancer. 1997, Vol. 75, No. 5, pages 634-638, especially page 634.	1-5
P,Y	AN, G. et al. Cloning of Prostate-Specific Genes that are Suppressed in Metastatic Prostate Cancer by a PCR Southern Differential Hybridization Method. Cell and Tumor Biology. March 1998, Vol. 39, page 208, especially page 208.	1-6

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 AUGUST 1999

Date of mailing of the international search report

09 SEP 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

YVONNE EYLER

Telephone No. (703) 308-0196